Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177810 · ClinicalTrials.gov registry record · Phase 2
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04177810 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 25 participants.
The verdict
NCT04177810, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
Interventions
- DRUG Cemiplimab
- DRUG Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2023-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177810
The ClinicalTrials.gov registry entry for NCT04177810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04177810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177810 about?
NCT04177810 is a clinical study titled "Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer". The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
What is the current status of trial NCT04177810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-11-16. Estimated completion is 2023-05-19.
What interventions are being tested in trial NCT04177810?
The interventions under investigation include: Cemiplimab (DRUG), Plerixafor (DRUG).
Who is sponsoring clinical trial NCT04177810?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.